Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)

Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)

  • November 2016 •
  • 58 pages •
  • Report ID: 4420177 •
  • Format: PDF
Scope of the Report

The report entitled “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biosimilar market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies of the companies.

Company Coverage

Sandoz
Amgen
Celltrion
Pfizer

Executive Summary

Majority of biosimilars are in pipeline as most of the major biologics have either already expired or are about to lose their patent in the next two years which act as a major driving force for the biosimilar market. Four major biologics namely Humira, Enbrel, Remicade and Infliximab patents are set to expire in December 2016, incentivizes a large number of companies to enter into biosimilar market.

The biosimilar market is in its early stages, but is expected to grow in the next five years. The global biosimilar market is supported by various growth drivers such as growing pressure to curtail healthcare expenditure, patent expiries of major biopharmaceuticals, rising chronic disease among aging population and positive outcomes in ongoing clinical trials etc. Yet the market faces some challenges, such as restrict entry of new players, the complexity of manufacturing biosimilars and clinical limitations including patient recruitment obstacles.
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.